D
David Irwin
Researcher at University of Colorado Denver
Publications - 108
Citations - 4909
David Irwin is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Hypoxia (medical) & Multiple myeloma. The author has an hindex of 32, co-authored 100 publications receiving 4529 citations. Previous affiliations of David Irwin include Anschutz Medical Campus & Colorado State University.
Papers
More filters
Journal ArticleDOI
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
Paul G. Richardson,Hannah R. Briemberg,Sundar Jagannath,Patrick Y. Wen,Bart Barlogie,James R. Berenson,Seema Singhal,David S. Siegel,David Irwin,Michael W. Schuster,Gordan Srkalovic,Raymond Alexanian,S. Vincent Rajkumar,Steven A. Limentani,Melissa Alsina,Robert Z. Orlowski,Kevin Najarian,Dixie Lee Esseltine,Kenneth C. Anderson,Anthony A. Amato +19 more
TL;DR: Bortezomib-associated peripheral neuropathy seemed reversible in the majority of patients after dose reduction or discontinuation, and the overall occurrence was independent of baseline neuropathy or type of prior therapy.
Journal ArticleDOI
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,Melissa Alsina,Vincent Rajkumar,Martha Q. Lacy,Andrzej Jakubowiak,William S. Dalton,Anthony Boral,Dixie-Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +23 more
TL;DR: The activity of bortezomib is confirmed and support extended treatment in relapsed multiple myeloma patients tolerating therapy and among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response.
Journal ArticleDOI
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
Sundar Jagannath,Brian G.M. Durie,Jeffrey L. Wolf,Elber Camacho,David Irwin,Jose Lutzky,Marti McKinley,Eli Gabayan,Amitabha Mazumder,David P. Schenkein,John Crowley +10 more
TL;DR: Bortezomib alone or in combination with dexamethasone is an effective induction therapy with a high CR and nCR rate and manageable toxicities in previously untreated patients with myeloma.
Journal ArticleDOI
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
Sundar Jagannath,Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,J. M. Cowan,Kenneth C. Anderson +9 more
TL;DR: Matched-pairs analyses suggest that bortezomib may overcome some of the poor impact of del(13) as an independent prognostic factor, however, sample sizes were very small; these findings require confirmation from further studies.
Journal ArticleDOI
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
Sundar Jagannath,Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,David Irwin,Gordan Srkalovic,David P. Schenkein,Dixie Lee Esseltine,Kenneth C. Anderson +9 more
TL;DR: Addition of dexamethasone to bortezomib in patients with relapsed and/or refractory multiple myeloma who had suboptimal responses to bortsomib alone was associated with improvement in responses without prohibitive toxicity.